Poultice

By adding fatty acid alkyl esters or dicarboxylic acid esters, the poultice maintains adhesive strength and prevents peel strength increase, addressing the issues of adhesive degradation and skin irritation.

JP7595702B2Active Publication Date: 2024-12-06HISAMITSU PHARM CO INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2023081829
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-12-06
Estimated Expiration
2040-01-23

AI Technical Summary

Technical Problem

Poultices containing poly(methyl acrylate/2-ethylhexyl acrylate) experience a decrease in adhesive strength and increased peel strength over time, leading to potential skin irritation and discomfort upon removal.

Method used

Incorporating fatty acid alkyl esters or dicarboxylic acid esters into the poultice composition enhances peel strength without impairing adhesion, maintaining adhesive strength over 24 hours.

Benefits of technology

The poultice maintains excellent adhesion and prevents an increase in peel strength, ensuring comfortable and effective skin application for an extended period.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595702000001
    Figure 0007595702000001
  • Figure 0007595702000002
    Figure 0007595702000002
Patent Text Reader

Abstract

To provide a plaster that does not lose its adhesive strength and shows little increase in its peel strength even after kept bonded all day.SOLUTION: Provided is a method for suppressing peel strength enhancement in a plaster comprising a plaster layer on a support and further comprising a release liner on the surface opposite to the support with respect to the plaster layer, the method comprising mixing a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of fatty acid alkyl ester and alkylene dicarboxylic acid ester to obtain the plaster and spreading it onto the support or the release liner, and the loss elastic modulus of the plaster layer after the release liner of the plaster was peeled off and allowed to stand for 24 hours in the environment with a temperature of 25°C and a relative humidity of 55% being 3000 to 7000 Pa in the condition with a frequency of 15 Hz and a measurement temperature of 32°C.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a poultice. [Background technology]

[0002] A cataplasm is a type of patch produced by spreading a drug-containing paste layer on a support such as cloth, and generally contains a lot of water, has a thick paste layer, and is characterized by low skin irritation. In addition, the adhesive strength of a cataplasm often decreases over time after application, and the development of a cataplasm that does not lose adhesive strength even when applied for a long period of time is being considered (Patent Documents 1 to 4).

[0003] Patent Document 1 discloses that the inclusion of poly(methyl acrylate / 2-ethylhexyl acrylate) in a cataplasm containing a partially neutralized polyacrylic acid can suppress a decrease in adhesive strength. Patent Document 2 discloses that the inclusion of polyacrylic acid in the plaster layer results in a cataplasm with excellent moldability and shape retention. In addition, since the cataplasm contains a drug in the hydrous plaster layer, the skin permeability of the drug tends to be lower in comparison with a tape (e.g., Patent Document 3). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2006 / 090782 [Patent Document 2] International Publication No. 2015 / 025935 [Patent Document 3] International Publication No. 2015 / 129808 [Patent Document 4] Japanese Patent Application Publication No. 10-95728 Summary of the Invention [Problem to be solved by the invention]

[0005] The present inventors have found that after a cataplasm containing poly(methyl acrylate / 2-ethylhexyl acrylate) is applied for one day, the peel strength of the plaster layer increases, and pain may occur when peeled off. Therefore, an object of the present invention is to provide a cataplasm that does not lose its adhesive strength and is unlikely to increase in peel strength even after application for one day. [Means for solving the problem]

[0006] As a result of investigations, the present inventors have found that adding a fatty acid alkyl ester or a dicarboxylate ester to a cataplasm containing poly(methyl acrylate / 2-ethylhexyl acrylate) can suppress the increase in peel strength without impairing adhesive strength.

[0007] That is, the present invention provides the following [1] to [4]. [1] A poultice comprising a paste layer on a support, a release liner is further provided on the surface of the paste layer opposite the support, the paste layer contains a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of a fatty acid alkyl ester and an alkylene dicarboxylate ester; A poultice preparation in which, after the release liner has been removed and the poultice is allowed to stand for 24 hours in an environment having a temperature of 25°C and a relative humidity of 55%, the loss modulus of the plaster layer is 3000 to 7000 Pa under conditions of a frequency of 15 Hz and a measurement temperature of 32°C. [2] The poultice described in [1], wherein the physiologically active substance is ketoprofen or a pharma- ceutically acceptable salt thereof. [3] The poultice according to [1] or [2], wherein the fatty acid alkyl ester comprises at least one selected from the group consisting of hexyl laurate, isopropyl myristate, and isopropyl palmitate. [4] The poultice according to any one of [1] to [3], wherein the alkylene dicarboxylate ester comprises diisopropyl adipate.

[0008] The present inventors believe that by adding a fatty acid alkyl ester or an alkylene dicarboxylate ester to a cataplasm containing poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate), the loss modulus (G") in the high frequency range (particularly 15 Hz) of the plaster layer will reach a specified value, making it possible to suppress an increase in peel strength. Effect of the Invention

[0009] According to the present invention, a poultice can be provided which not only has excellent adhesiveness, but also does not lose its adhesive strength even after being applied for one day, and is resistant to increase in peel strength.

[0010] In this specification, "excellent adhesion" means that in a probe tack test, the measured value of the force (peel strength) required to peel off after a specified cylindrical probe is brought into contact with the adhesive surface of the patch for a short time is 0.2 N or more, or in an inclined ball tack test, a cataplasm is placed on an inclined plate set at an inclination angle of 30° so that the support surface is in contact with the inclined plate, the release liner is peeled off, and a ball with a diameter of 9 / 32 inches or more is placed 100 mm from the top end of the support, and the ball stops on the paste layer. The distance from the top end of the support to where the ball is placed is called the runway. The probe tack test can be performed according to the description of the 17th revised Japanese Pharmacopoeia. The inclined ball tack test can be performed according to the description of JIS Z0237:2009 or the 17th revised Japanese Pharmacopoeia.

[0011] As used herein, "enhanced peel strength" means that the peel strength of the paste layer after storage under a specified environment is increased compared to the peel strength of the paste layer at the completion of production of the poultice.

[0012] In this specification, the high frequency region, which is a measurement condition for the loss modulus, means a range of 15 to 50 Hz. According to the Adhesive Handbook, 3rd Edition (published by the Japan Adhesive Tape Industry Association in 2005), the frequency related to the destructive process such as peeling and tack is 10 2 rad / s (approximately 16Hz), and the contact process of finger tack, polyken probe tack, loop tack, etc. is 10 to 10 -1 rad / s (approximately 0.016 to 1.6 Hz), the shear deformation process in the retention test is 10 -2 rad / s (approximately 0.0016Hz). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Preferred embodiments of the present invention will now be described in detail.

[0014] A poultice according to one embodiment of the present invention is a poultice comprising a paste layer on a support and further comprising a release liner on the side of the paste layer opposite the support, the paste layer containing a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of a fatty acid alkyl ester and an alkylene dicarboxylate ester, and after the release liner is peeled off and the paste layer is allowed to stand for 24 hours in an environment at a temperature of 25°C and a relative humidity of 55%, the loss modulus of the paste layer is 3000 to 7000 Pa under conditions of a frequency of 15 Hz and a measurement temperature of 32°C.

[0015] The support may be any one that can support the water-containing paste, and may be any one known to those skilled in the art. Examples of the support include woven fabric (including knitted fabric), nonwoven fabric, resin film, foam sheet, and paper. When using woven fabric, nonwoven fabric, or resin film as the support, the material may include, for example, polyolefins such as polyethylene, polypropylene, and polybutylene, polyesters such as polyethylene terephthalate, rayon, polyurethane, and cotton, and these may be used alone or in combination of two or more. Polyester is more preferable as the material of the support.

[0016] The support is preferably a nonwoven fabric or a woven fabric, and particularly preferably a nonwoven fabric or a woven fabric having a predetermined elongation recovery rate (elongation elasticity). In this specification, "elongation recovery rate" is a value measured according to the description in JIS L1096:2010, and means "elongation elasticity at constant load" or "elongation elasticity at constant rate elongation". For example, "50% elongation recovery rate" is the elongation elasticity when elongated to an elongation rate of 50% (constant rate elongation), and "load at 50% elongation" is the load (constant load) required to elongate to an elongation rate of 50%. By using a nonwoven fabric or a woven fabric having a predetermined elongation recovery rate, the support expands and contracts according to the movement of the application site when applied to a movable part such as a joint, and is therefore preferable.

[0017] When the support is a nonwoven fabric, for example, the recovery rate of the nonwoven fabric at 50% elongation is 60 to 99%, preferably 65 to 95%, and more preferably 70 to 90%. The load of the nonwoven fabric at 50% elongation is, for example, 1 to 5 N / 2.5 cm in the longitudinal direction (long axis direction) and 0.1 to 3 N / 2.5 cm in the transverse direction (short axis direction). The basis weight of the suitable support is, for example, 80 to 120 g / m 2 90-110g / m 2 It is preferable that the thickness of the support is, for example, 0.5 to 2 mm. The bending resistance of the support (the bending resistance is measured by JIS L1096:2010, Method A (45° cantilever method)) can be, for example, 20 to 40 mm in the longitudinal direction (long axis direction) and 10 to 35 mm in the transverse direction (short axis direction), and is preferably 25 to 35 mm in the longitudinal direction (long axis direction) and 15 to 30 mm in the transverse direction (short axis direction).

[0018] The thickness of the nonwoven fabric as the support is preferably 0.5 to 2 mm. The basis weight of the nonwoven fabric as the support is preferably 80 to 150 g / m 2 It is preferable that:

[0019] The knitted fabric used as the support also includes knitted fabrics processed into a cloth by assembling stitches by circular knitting, warp knitting, weft knitting, etc. Knitted fabrics made of one or a combination of two or more materials such as polyester, nylon, polypropylene, rayon, etc. are preferred, and among them, knitted fabrics made of polyethylene terephthalate, which has little interaction with drugs, are more preferred.

[0020] In particular, when the support is a woven fabric, the 50% elongation recovery rate of the woven fabric is, for example, 60 to 99%, preferably 65 to 95%, and more preferably 70 to 90%. The load at 50% elongation is, for example, 1 to 5 N / 2.5 cm in the longitudinal direction (long axis direction) and 0.1 to 3 N / 2.5 cm in the transverse direction (short axis direction). The bending resistance of the support can be, for example, 10 to 30 mm in the longitudinal direction (long axis direction) and 10 to 30 mm in the transverse direction (short axis direction), and is preferably 15 to 25 mm in the longitudinal direction (long axis direction) and 15 to 25 mm in the transverse direction (short axis direction).

[0021] The thickness of the woven fabric as the support is preferably 0.5 to 2 mm.

[0022] In particular, the basis weight is 80 to 150 g / m 2 When the polyethylene terephthalate woven fabric is used, the water contained in the paste is less likely to seep out through the meshes of the woven fabric during spreading, and the anchoring property between the woven fabric and the paste is more excellent.

[0023] In addition, the polyethylene terephthalate woven fabric preferably has a longitudinal (longitudinal) modulus of 2 to 12 N / 5 cm and a transverse (short-axis) modulus of 2 to 8 N / 5 cm (the modulus is measured according to JIS L1018:1999). If the modulus is lower than 2 N / 5 cm, the woven fabric may stretch when the paste is spread, causing the adhesive to soak into the mesh, resulting in a decrease in functionality as a poultice. If the modulus is higher than 12 N / 5 cm (longitudinal) or 8 N / 5 cm (transverse), the elasticity is poor and it may be difficult to follow the expansion of the skin when applied to a moving part.

[0024] The paste layer contains a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of fatty acid alkyl ester and alkylene dicarboxylate ester.

[0025] The physiologically active substance may be any substance that is absorbable through the skin and exhibits pharmacological activity in the living body. Examples of physiologically active substances include non-steroidal anti-inflammatory agents such as ketoprofen, felbinac, flurbiprofen, diclofenac, diclofenac sodium, methyl salicylate, glycol salicylate, indomethacin, and ketoprofen, or esters thereof, antihistamines such as diphenhydramine, analgesics such as aspirin, acetaminophen, ibuprofen, and loxoprofen sodium, local anesthetics such as lidocaine, muscle relaxants such as suxamethonium chloride, antifungal agents such as clotrimazole, antihypertensive agents such as clonidine, vasodilators such as nitroglycerin and isosorbide dinitrate, vitamins such as vitamin A, vitamin E (tocopherol), tocopherol acetate, vitamin K, octothiacin, and riboflavin butyrate, prostaglandins, scopolamine, fentanyl, l-menthol, capsicum extract, and vanillylamide nonylate. Some physiologically active substances have two optical isomers, R- and S-, and the physiologically active substance used in the present embodiment may be either one of the optical isomers or a mixture of the two optical isomers in any ratio.

[0026] Examples of pharma- ceutically acceptable salts of physiologically active substances include inorganic salts such as sodium salts, potassium salts, calcium salts, etc.; amine salts such as monoethanolamine and diethanolamine salts, etc.

[0027] The content of the physiologically active substance in the paste layer is 1.5 to 2.5% by mass, and preferably 1.8 to 2.2% by mass, based on the mass of the entire paste layer. When the paste layer contains a pharma- ceutically acceptable salt of the physiologically active substance, the content ratio of each component is calculated by converting the mass of the salt into the mass of the physiologically active substance (free form).

[0028] The water content in the paste layer may be 30 to 60% by mass, or 35 to 50% by mass, based on the total mass of the paste layer.

[0029] The paste layer may further contain at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate). Poly(methyl acrylate / 2-ethylhexyl acrylate) is a copolymer of methyl acrylate and 2-ethylhexyl acrylate. Poly(methacrylic acid / n-butyl acrylate) is a copolymer of methacrylic acid and n-butyl acrylate. The content ratio of each monomer is not particularly limited.

[0030] Poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be in the form of an emulsion (aqueous emulsion) dispersed in any solvent such as water or a water-containing organic solvent. An example of an aqueous emulsion of poly(methyl acrylate / 2-ethylhexyl acrylate) is Nicasol TS-620 (trade name, manufactured by Nippon Carbide Industries Co., Ltd.). An example of an aqueous emulsion of poly(methacrylic acid / n-butyl acrylate) is Primal N-580NF (trade name, manufactured by Rohm and Haas Co., Ltd.) and Ultrasol W-50 (trade name, manufactured by Aica Kogyo Co., Ltd.). When preparing a plaster fluid for a cataplasm, these copolymers are mixed with other components in the form of an aqueous emulsion, which makes it easier for these polymers to disperse throughout the plaster fluid. By dispersing these copolymers throughout the plaster layer, a more significant effect of suppressing the decrease in adhesive strength can be obtained, and sufficient adhesive strength can be exhibited even after a longer application.

[0031] The content of poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be 2.75 to 15.75 mass% in terms of solids based on the total mass of the paste layer, and is preferably 3.3 to 13.86 mass%, 5.5 to 12.6 mass%, or 5.5 to 11.34 mass%.

[0032] The content of the aqueous emulsion of poly(methyl acrylate / 2-ethylhexyl acrylate) or poly(methacrylic acid / n-butyl acrylate) may be 5-25% by mass (2.75-15.75% by mass as solid content) based on the total mass of the paste layer, and is preferably 6-22% by mass (3.3-13.86% by mass as solid content), 10-20% by mass (5.5-12.6% by mass as solid content), or 10-18% by mass (5.5-11.34% by mass as solid content). For example, in Nicasol TS-620, the aqueous emulsion contains 55-63% poly(methyl acrylate / 2-ethylhexyl acrylate) as solid content. When the aqueous emulsion of the above polymer is used to produce a poultice, the water content in the paste layer described above also includes the amount of water added as a medium for the aqueous emulsion.

[0033] The fatty acid alkyl ester may be an ester synthesized from a fatty acid and an alkyl alcohol (alkanol). The alkyl alcohol may be, for example, an alkyl alcohol having 1 to 10 carbon atoms. In this specification, the fatty acid means a saturated or unsaturated alkyl carboxylic acid having 8 to 18 carbon atoms. Examples of the fatty acid alkyl ester include caprylic acid alkyl ester, capric acid alkyl ester, lauric acid alkyl ester, myristate acid alkyl ester, palmitic acid alkyl ester, palmitoleic acid alkyl ester, stearate acid alkyl ester, and oleic acid alkyl ester. Preferred fatty acid alkyl esters are hexyl laurate, isopropyl myristate, and isopropyl palmitate. By containing a fatty acid alkyl ester, the loss modulus can be adjusted to a predetermined range, and the skin permeability of a physiologically active substance can be improved.

[0034] The content of the fatty acid alkyl ester in the paste layer may be 1 to 20% by mass, preferably 1 to 15% by mass or 2 to 13% by mass, based on the total mass of the paste layer. In particular, the content of hexyl laurate may be 0.5 to 10% by mass, preferably 0.5 to 5.0% by mass or 1.0 to 3.5% by mass, based on the total mass of the paste layer. When the content of hexyl laurate, isopropyl myristate or isopropyl palmitate is 0.5 to 5.0% by mass, the loss modulus can be more easily adjusted to a predetermined range, and the skin permeability of the physiologically active substance is particularly excellent.

[0035] The alkylene dicarboxylic acid ester may be an ester synthesized from an alkylene dicarboxylic acid and a linear or branched alkyl alcohol. The alkyl alcohol may be, for example, an alkyl alcohol having 1 to 10 carbon atoms. In this specification, the alkylene dicarboxylic acid is a compound having carboxy groups at both ends of an alkylene group having 1 to 8 carbon atoms. Examples of such alkylene dicarboxylic acids include ethanedioic acid (oxalic acid), propanedioic acid (malonic acid), butanedioic acid (succinic acid), pentanedioic acid (glutaric acid), hexanedioic acid (adipic acid), heptanedioic acid (pimelic acid), octanedioic acid (suberic acid), nonanedioic acid (azelaic acid), and decanedioic acid (sebacic acid). Specific examples of the alkylene dicarboxylic acid ester are diethyl adipate, diisopropyl adipate, diethyl sebacate, and diisopropyl sebacate. The alkylene dicarboxylic acid ester may be used alone or in combination of two or more. The above-mentioned fatty acid alkyl esters and alkylene dicarboxylic acid esters may also be combined.

[0036] The content of the alkylene dicarboxylate in the paste layer may be 1 to 20% by mass, preferably 1 to 15% by mass or 2 to 13% by mass, based on the total mass of the paste layer. In particular, the content of diisopropyl adipate may be 0.5 to 10% by mass, preferably 0.5 to 5.0% by mass or 1.0 to 3.5% by mass, based on the total mass of the paste layer. When the content of diisopropyl adipate is 0.5 to 5.0% by mass, it becomes easier to adjust the loss modulus to a predetermined range, and the skin permeability of the physiologically active substance is particularly excellent.

[0037] The paste layer may further contain a neutralized polyacrylic acid. The neutralized polyacrylic acid may be a completely neutralized polyacrylic acid, a partially neutralized polyacrylic acid, or a mixture thereof. The neutralized polyacrylic acid may be a polyacrylic acid salt, such as a sodium salt, a potassium salt, a calcium salt, or an ammonium salt.

[0038] As the neutralized polyacrylic acid, a partially neutralized polyacrylic acid is preferred because it has high initial adhesion and adhesion over time. The partially neutralized polyacrylic acid is one in which structural units derived from acrylic acid and structural units derived from acrylic acid salts are present in any ratio in one polymer chain. As the partially neutralized polyacrylic acid, one in which 50 mol % of the carboxyl groups in one polymer chain are neutralized is preferably used.

[0039] The content of the neutralized polyacrylic acid in the paste layer is preferably 1 to 6% by mass, more preferably 2 to 6% by mass, based on the total mass of the paste layer. When the content of the neutralized polyacrylic acid is 1% by mass or more, the adhesive strength of the paste layer is sufficiently high and the paste layer is less likely to fall off. When the content of the neutralized polyacrylic acid is 6% by mass or less, the moldability and shape retention of the paste layer are improved.

[0040] The paste layer may further contain polyacrylic acid. By containing polyacrylic acid, the adhesive force retention performance is maintained high and the shape retention of the cataplasm is improved. The content of polyacrylic acid is preferably 1 to 5 mass% based on the mass of the paste layer. When the content of polyacrylic acid is 1 mass% or more, the moldability and shape retention of the paste layer are improved. When the content of polyacrylic acid is 5 mass% or less, the hardness of the paste layer is unlikely to increase, and the adhesion to the skin is increased. By containing both a neutralized polyacrylic acid and polyacrylic acid, the adhesiveness, moldability, shape retention, and hardness of the cataplasm are improved in a well-balanced manner.

[0041] The paste layer may contain other ingredients such as plant-derived ingredients, animal-derived ingredients, water-soluble polymers, solubilizing agents, crosslinking agents, moisturizing agents, cooling agents, stabilizers, inorganic powders, colorants, flavoring agents, and pH adjusters.

[0042] The plant-derived component may be a component extracted from at least a part of a plant (e.g., leaves, roots, skin, fruit) or a hydrolysate thereof, and examples thereof include fruit-derived components such as apple extract, orange extract, orange juice, raspberry extract, kiwi extract, cucumber extract, gardenia extract, grapefruit extract, crawthorn extract, Japanese pepper extract, hawthorn extract, juniper extract, oak extract, duke extract, tomato extract, grape extract, loofah extract, lime juice, apple extract, apple juice, lemon extract, and lemon juice, allantoin, lecithin, amino acids, kojic acid, and components extracted from various herbal medicines such as aloe and licorice.In addition, the plant-derived ingredients are Angelica extract, Avocado extract, Hydrangea extract, Arnica extract, Ginkgo extract, Fennel extract, Turmeric extract, Oolong tea extract, Scutellaria extract, Phellodendron bark extract, Barley extract, Dutch mustard extract, Seaweed extract, Hydrolyzed elastin, Hydrolyzed wheat powder, Chamomilla extract, Artemisia capillaris extract, Licorice extract, Karkade extract, Guanosine, Sasa kumazasa extract, Walnut extract, Clematis extract, Burdock extract, Comfrey extract, Cowberry extract, Bupleurum extract, Salvia extract, Soapwort extract, Bamboo grass extract, Crataegus crenata extract, Shiitake mushroom extract, Rehmannia extract, Lithospermum root extract, Tilia extract, Spiraea japonica extract, Calamus root extract, Birch extract, Horsetail extract, Honeysuckle extract, Ivy extract, Crataegus monogyna extract, Elderberry extract extract, yarrow extract, peppermint extract, mallow extract, swertia japonica extract, tsargassum extract, thyme extract, clove extract, Imperata cylindrica extract, chinpi extract, spruce extract, dokudami extract, natto extract, carrot extract, wild rose extract, hibiscus extract, bamboo root extract, parsley extract, parietaria extract, sedge extract, bisabolol, coltsfoot extract, butterbur bud extract, podiatrist extract, butcher's broom extract, propolis, peppermint extract, linden extract, hop extract, pine extract, horse chestnut extract, skunk cabbage extract, soapberry extract, peach leaf extract, cornflower extract, eucalyptus extract, yuzu extract, mugwort extract, lavender extract, lettuce extract, astragalus extract, rose extract, rosemary extract, Roman chamomile extract, and the like.

[0043] The animal-derived component may be a component extracted from at least a part of an animal (e.g., placenta, umbilical cord) or a hydrolysate thereof, or a component produced by an animal, and examples thereof include placenta extract, umbilical cord extract, water-soluble placenta extract, hydrolyzed silk, honey, royal jelly extract, and yeast extract.

[0044] The water-soluble polymer is not particularly limited as long as it can retain moisture in the poultice, and those generally known to those skilled in the art can be used. Examples of the water-soluble polymer include gelatin, polyvinyl alcohol, polyvinylpyrrolidone, sodium alginate, hydroxypropyl cellulose, sodium carboxymethylcellulose (carmellose sodium), methylcellulose, and carrageenan. One type may be used alone, or two or more types may be used in combination. The water-soluble polymer is preferably carmellose sodium, gelatin, or polyvinyl alcohol. The content of the water-soluble polymer may be 3 to 20% by mass, and preferably 3 to 10% by mass, based on the mass of the paste layer.

[0045] The solubilizing agent is not particularly limited as long as it can dissolve the drug, and examples thereof include crotamiton, N-methylpyrrolidone, polyalkylene glycols such as polyethylene glycol (PEG) and polybutylene glycol, oxyalkylene fatty acid esters such as polyethylene glycol monostearate, polyoxyalkylene sorbitan fatty acid esters such as polysorbate 80, surfactants such as polyoxyethylene hydrogenated castor oil, and glycols such as propylene glycol. These solubilizing agents may be used alone or in combination of two or more. The content of the solubilizing agent is preferably 0.1 to 10% by mass based on the mass of the paste layer.

[0046] The crosslinking agent is a component for adjusting the progress of the crosslinking reaction between the neutralized polyacrylic acid and the crosslinking reaction between the neutralized polyacrylic acid and the polyacrylic acid added optionally, and may be one generally used in the industry. Examples of the crosslinking agent include aluminum compounds. The content of the crosslinking agent is preferably 0.01 to 6% by mass based on the mass of the paste layer. When the content of the crosslinking agent is within this range, a poultice with better skin conformability can be obtained.

[0047] The moisturizing agent is not particularly limited as long as it can suppress the evaporation of water from the paste layer over time. Examples of the moisturizing agent include polyhydric alcohols such as concentrated glycerin, sorbitol, ethylene glycol, 1,4-butanediol, polyethylene glycol, and liquid paraffin. These moisturizing agents may be used alone or in combination of two or more. Concentrated glycerin is preferred as the moisturizing agent. The content of the moisturizing agent is preferably 20 to 40% by mass based on the mass of the paste layer.

[0048] Examples of the cooling agent include thymol, l-menthol, dl-menthol, l-isopulegol, and peppermint oil. A preferred cooling agent is l-menthol. The content of the cooling agent may be 0.1 to 3% by mass, and preferably 0.5 to 3% by mass, based on the total mass of the paste layer. The content of l-menthol is preferably 0.1 to 0.5% by mass, and more preferably 0.2 to 0.4% by mass, based on the total mass of the paste layer. If the content of l-menthol is 0.1% by mass or more, the user of the poultice can be given a sufficient cooling sensation. If the content of l-menthol is 0.5% by mass or less, the storage stability of ketoprofen is more excellent.

[0049] Examples of stabilizers include oxybenzone, dibutylhydroxytoluene (BHT), sodium edetate, UV absorbers (for example, dibenzoylmethane derivatives), etc. The content of the stabilizer is preferably 0.5 to 3% by mass based on the mass of the paste layer.

[0050] The mass of the paste layer is 214 to 1000 g / m 2 and 400 to 1000 g / m 2 and 400 to 650 g / m 2 Preferably, the thickness is 400 to 650 g / m 2When the mass of the paste layer is within the above range, the overall thickness of the poultice can be reduced, the poultice can easily conform to the skin, and the difference in level with the peripheral edge when applied is reduced, so that the poultice tends not to peel off.

[0051] The pH of the paste layer is preferably 4 to 8, more preferably 4.5 to 6. By setting the pH at 4 or higher, irritation to the skin is reduced, and by setting the pH at 8 or lower, the moldability and shape retention of the poultice can be improved. In particular, when the support is a woven fabric, particularly a knitted fabric, bleeding may occur when the paste layer is formed, but bleeding tends to be suppressed when the pH is 5 to 6.5. The pH can be measured, for example, according to the pH measurement method of the general test method of the Japanese Pharmacopoeia, using a glass composite electrode and diluting the sample 20 times with purified water.

[0052] The poultice has a release liner on the side of the paste layer opposite the support, which tends to inhibit a decrease in the water content of the paste layer during storage and reduce adhesion of dirt and the like to the paste layer.

[0053] The material of the release liner is not particularly limited, and a liner made of a material generally known to those skilled in the art can be used. When a woven fabric, a nonwoven fabric, a knitted fabric, or a resin film is used as the support, the material of the release liner can be, for example, polyethylene, polypropylene, polybutylene, polyethylene terephthalate, rayon, or polyurethane, and one type can be used alone or two or more types can be used in combination. The material of the release liner is preferably polypropylene film.

[0054] The poultice may be stored inside a pouch. By storing the poultice inside a pouch, a decrease in the water content of the paste layer can be suppressed, and adhesion of dirt and the like to the paste layer can be reduced.

[0055] The poultice can be produced, for example, by mixing a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of a fatty acid alkyl ester and an alkylene dicarboxylate ester, adding the optional ingredients described above to obtain a paste liquid, spreading this paste liquid evenly on a release liner, and laminating a support thereon.

[0056] The cataplasm according to the present embodiment has a loss modulus of 3000 to 7000 Pa, preferably 5000 to 7000 Pa, when the cataplasm is left to stand for 24 hours in an environment with a temperature of 25°C and a relative humidity of 55% after the release liner is peeled off and then subjected to a viscoelasticity test under conditions of a frequency of 15 Hz and a measurement temperature of 32°C. The cataplasm can be produced by spreading the cataplasm on a support and then laminating the release liner. Alternatively, the cataplasm may be produced by spreading the cataplasm on a release liner and then laminating the support. The loss modulus is preferably a value measured after the cataplasm is produced by the above method, the release liner is peeled off, and then the cataplasm is left to stand for 24 hours in an environment with a temperature of 25°C and a relative humidity of 55%. EXAMPLES

[0057] The present invention will be described in more detail below with reference to examples and comparative examples.

[0058] A plaster liquid was obtained by mixing the components shown in Table 1 for a certain period of time. The obtained plaster liquid was evenly spread on a release liner so that the plaster mass per poultice (140 mm x 100 mm) was 6 g, and then a knitted fabric (backing material) was immediately laminated thereon to produce a poultice.

[0059] [Table 1]

[0060] Test 1: Probe tack test The release liner was removed from each patch, and the probe tack was evaluated under the following test conditions: In addition, to simulate the adhesive strength 24 hours after application to the skin, the manufactured patches were left to stand for 24 hours at a temperature of 25°C and a relative humidity of 55% with the release liner removed, and then the probe tack test was carried out in the same manner. [Test conditions] Equipment: Probe tack tester (manufactured by Tester Sangyo Co., Ltd.) Probe: Bakelite probe Contact speed: 1cm / sec Contact time: 1 second Retaining ring: Brass 20g

[0061] Test 2: Ball tack test The release liner was removed from each poultice (size: 50 mm x 100 mm), and a ball tack test was performed according to the method described in JIS Z0237:2009. The poultice was placed on the inclined plate of the ball rolling device so that the plaster surface (the surface to be applied to the skin) of the poultice was facing up. The inclination angle of the inclined plate was 30°. When a ball having a specified diameter was placed at a position (start position) 100 mm (runway) from the top end (upper edge) of the plaster layer, it was evaluated whether the ball rolled on the inclined plate and remained on the plaster layer for 5 seconds or more. The sizes of the balls placed were 32 types, each increasing by 1 / 32 inch from a ball with a diameter of 1 / 32 inch, and the diameter of the largest ball was 1 inch (32 / 32 inch). The diameter of the ball with the largest diameter among the balls that stopped without passing over the plaster layer was recorded.

[0062] Test 3: 180° peel strength test The prepared cataplasm was cut into a rectangle with a width of 2.5 cm and attached to a test plate. The cataplasm was pressed with a roller and then peeled off at a constant speed under the following test conditions. The load required to peel off the cataplasm (peel strength) was measured. In addition, in order to estimate the intensity of pain when the patch is peeled off 24 hours after application to the skin, the release liner was removed from the prepared patch and the patch was pressed against a test plate with a roller and left to stand for 24 hours under conditions of a temperature of 25°C and a relative humidity of 55%, and then a 180° peel strength test was performed in the same manner. [Test conditions] Equipment: Tensilon type tensile testing machine (product name: RTA-100, manufactured by A&D Co., Ltd.) Test plate: PTFE plate Peeling speed: 300mm / min

[0063] Test 4: Viscoelasticity test Assuming the adhesive strength 24 hours after application to the skin, the prepared cataplasm was left to stand for 24 hours at a temperature of 25°C and a relative humidity of 55% with the release liner removed, and then the loss modulus was measured under the following measurement conditions. Of the loss moduli obtained, the loss modulus at a frequency of 15 Hz was recorded. [Measurement conditions] Equipment: Rheometer HAAKE MARS-III (manufactured by Thermo Fisher Scientific Co., Ltd.) Sample: 20mm diameter parallel plate Gap distance: 1mm Sample size: 0.7g Temperature: 32℃ Frequency: 0.01~100Hz Distortion: 1%

[0064] The results are shown in Table 2. In the poultices of Examples 1 to 5, the increase in peel strength was significantly suppressed even after being left to stand for 24 hours, compared with the poultices of Comparative Examples 1 and 2. Meanwhile, no significant difference was observed in the probe tack value between the Examples and Comparative Examples, and adhesive strength was maintained. In Comparative Example 1, the loss tangent (tan δ) value was higher than the other poultices in the range of 0.1 to 100 Hz. In Comparative Example 2, the storage modulus (G') was higher than the other poultices in the range of 0.01 to 100 Hz.

[0065] [Table 2]

[0066] Except for using diclofenac sodium, indomethacin, felbinac or flurbiprofen instead of ketoprofen, poultices (Examples 6 to 9) were produced in the same manner as in Example 1. All of the poultices of Examples 6 to 9 showed good results in Tests 1 to 4.

Claims

1. A method for suppressing an increase in peel strength in a poultice comprising a paste layer on a support and a release liner on a surface opposite to the support with respect to the paste layer, comprising: The method includes a step of mixing a physiologically active substance, water, at least one of poly(methyl acrylate / 2-ethylhexyl acrylate) and poly(methacrylic acid / n-butyl acrylate), and at least one of a fatty acid alkyl ester and an alkylene dicarboxylate ester to obtain a plaster fluid, and spreading the plaster fluid on a support or a release liner; The release liner of the poultice is peeled off, and the poultice is allowed to stand for 24 hours in an environment having a temperature of 25°C and a relative humidity of 55%, after which the loss modulus of the plaster layer is 3000 to 7000 Pa under conditions of a frequency of 15 Hz and a measurement temperature of 32°C.

2. 2. The method of claim 1, wherein the biologically active agent is ketoprofen or a pharma- ceutically acceptable salt thereof.

3. The method according to claim 1 or 2, wherein the fatty acid alkyl ester comprises at least one selected from the group consisting of hexyl laurate, isopropyl myristate, and isopropyl palmitate.

4. The method of any one of claims 1 to 3, wherein the alkylene dicarboxylic acid ester comprises diisopropyl adipate.

Citation Information

Patent Citations

  • Gel preparation for transcutaneous absorption

    JP1991223212A

  • poultice

    JP1992346922A

  • Gelatinous material and therapeutic gel pharmaceutical using the same

    JP1993065224A

  • Anti-inflammatory analgesic agent for external use

    JP1994199701A

  • Pharmaceutical preparation for percutaneous administration

    JP1997315976A